Rutgers secures EUA for SARS-CoV-2 test

By staff writers

April 14, 2020 -- Rutgers University's RUCDR Infinite Biologics has secured an emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a SARS-CoV-2 test that may be used for screening saliva specimens as well as throat and nasopharyngeal swabs.

Andrew Brooks
Andrew Brooks, PhD, COO and director of technology development at RUCDR Infinite Biologics. Image courtesy of Rutgers University.

"The impact of this approval is significant," Andrew Brooks, PhD, chief operating officer (COO) and director of technology development at RUCDR, said in a statement released by the university. "It means we no longer have to put [healthcare] professionals at risk for infection by performing nasopharyngeal or oropharyngeal collections."

The TaqPath SARS-CoV-2 assay received the clearance on April 10 as a laboratory-developed test. With this type of EUA, tests are authorized for use in a single laboratory that is CLIA-certified to perform high-complexity tests. RUCDR Infinite Biologics is a cell and DNA repository that is part of the university's Human Genetics Institute of New Jersey. It developed the test in partnership with Spectrum Solutions and Accurate Diagnostic Labs (ADL).

"Collection of saliva specimens is limited to patients with symptoms of COVID-19 and should be performed in a healthcare setting under the supervision of a trained healthcare provider using the Spectrum Solutions SDNA-1000 Saliva Collection Device," the agency noted in a summary of the EUA. "Negative results for SARS-CoV-2 RNA from saliva should be confirmed by testing of an alternative specimen type if clinically indicated."

The tests are available to the RWJBarnabas Health network, which is New Jersey's most comprehensive healthcare system, according to the university.

What are the risks of false-negative COVID-19 tests?
Are healthcare providers and the public putting too much faith in the accuracy of diagnostic tests for COVID-19? An article published April 9 in Mayo...
Testing delays hamper hospitals in COVID-19 response
Delays and supply shortages of diagnostic tests for COVID-19 are having a ripple effect on the response of U.S. hospitals to the COVID-19 pandemic, according...
CAP lends a hand in COVID-19 testing
The College of American Pathologists (CAP) has released a proficiency testing program to help lab professionals evaluate their tests for the novel coronavirus...
Biocept to accept COVID-19 test orders in April
Biocept has verified its COVID-19 molecular diagnostic test and plans to begin accepting requests for the processing of tests ordered by physicians starting...
LabLynx debuts LIMS for COVID-19 testing
LabLynx has developed a laboratory information management system (LIMS) that is dedicated to COVID-19 diagnostic testing.

Copyright © 2020

Last Updated np 4/14/2020 8:00:04 AM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current